The tumor status of estrogen and progesterone receptors, which have already been shown to play a prognostic role, has previously been evaluated as predictive markers of response to endocrine therapy, including ERα expression or an ER histoscore > 200.8,9,19,33 However, although a large proportion of epithelial ovarian cancers express the ERα receptor, this factor alone does not seem to be sufficient to predict response to hormone therapy. This evidence concerns the gene ESR1 and neoplasm.